Success Metrics

Clinical Success Rate
82.1%

Based on 352 completed trials

Completion Rate
82%(352/429)
Active Trials
66(10%)
Results Posted
49%(174 trials)
Terminated
77(12%)

Phase Distribution

Ph early_phase_1
27
4%
Ph phase_1
79
12%
Ph phase_2
241
36%
Ph not_applicable
83
12%
Ph phase_3
127
19%
Ph phase_4
110
16%

Phase Distribution

106

Early Stage

241

Mid Stage

237

Late Stage

Phase Distribution667 total trials
Early Phase 1First-in-human
27(4.0%)
Phase 1Safety & dosage
79(11.8%)
Phase 2Efficacy & side effects
241(36.1%)
Phase 3Large-scale testing
127(19.0%)
Phase 4Post-market surveillance
110(16.5%)
N/ANon-phased studies
83(12.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.1%

352 of 475 finished

Non-Completion Rate

25.9%

123 ended early

Currently Active

66

trials recruiting

Total Trials

668

all time

Status Distribution
Active(76)
Completed(352)
Terminated(123)
Other(117)

Detailed Status

Completed352
unknown113
Terminated77
Withdrawn46
Recruiting43
Active, not recruiting23

Development Timeline

Analytics

Development Status

Total Trials
668
Active
66
Success Rate
82.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 127 (4.0%)
Phase 179 (11.8%)
Phase 2241 (36.1%)
Phase 3127 (19.0%)
Phase 4110 (16.5%)
N/A83 (12.4%)

Trials by Status

unknown11317%
withdrawn467%
terminated7712%
completed35253%
active_not_recruiting233%
enrolling_by_invitation10%
suspended41%
not_yet_recruiting91%
recruiting436%

Recent Activity

Clinical Trials (668)

Showing 20 of 668 trialsScroll for more
NCT04224493Phase 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Active Not Recruiting
NCT03031821Phase 3

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

Terminated
NCT07138443Not Applicable

Influence of Melatonin on Cardiovascular and Thermoregulatory Responses to Stress

Completed
NCT07714746Phase 3

Ivabradine in the Acute Management of Cardiogenic Shock

Recruiting
NCT03999099Phase 1

Targeting Orexin to Treat Nicotine Dependence

Active Not Recruiting
NCT03888222Phase 2

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Completed
NCT07611019Phase 2

Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial

Enrolling By Invitation
NCT06438471Phase 1

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

Recruiting
NCT07695246Not Applicable

Efficacy of CBT-I With Adjuvant Melatonin in Older Adults Chronic Insomnia

Not Yet Recruiting
NCT06843148Not Applicable

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Recruiting
NCT04264897Phase 3

Antecedent Metabolic Health and Metformin Aging Study

Completed
NCT02964884Phase 2

Interventions for Reading Disabilities in NF1

Active Not Recruiting
NCT03934905Phase 1

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Recruiting
NCT06563895Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Recruiting
NCT05441267Phase 4

A Study of Cardiovascular Events iN Diabetes Plus

Active Not Recruiting
NCT03762109Phase 2

The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery

Completed
NCT03514108Phase 4

DANHEART (H-HeFT and Met-HeFT)

Completed
NCT03295383Phase 3

Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid

Active Not Recruiting
NCT04098666Phase 2

Metformin in Alzheimer's Dementia Prevention

Active Not Recruiting
NCT04262206Phase 4

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
668